耐甲氧西林金葡菌感染的免疫治疗开发  

Development of immunotherapy for the treatment of methicillin-resistant Staphylococcus aureus infection

作　　者：胡敏[1] 李继安[1] 陈代杰[1] 

机构地区：[1]中国医药工业研究总院上海医药工业研究院创新药物与制药工艺国家重点实验室,上海200040

出　　处：《世界临床药物》2013年第2期101-105,共5页World Clinical Drug

基　　金：微生物药物技术创新与新药创制产学研联盟(项目编号:2010ZX09401-403)

摘　　要：耐甲氧西林金葡菌(MRSA)感染致病率和致死率不断上升,特别是万古霉素耐药金葡菌的出现,对人类健康构成了极大的威胁。尽管新型抗MRSA小分子化学药物的上市,对控制MRSA感染起到了重要的作用,但多个处于不同临床研究阶段的免疫治疗药物展现了独特的抗MRSA感染效果。本文简要综述针对MRSA感染的主动免疫和被动免疫治疗药物开发进展。The morbidity and mortality of the disease infected by methicillin-resistant Staphylococcus aureus （MRSA）have been increasing and threatening to human health in recent years. Especially, as the emergence of vancomycin-resistant Staphylococcus aureus, the situation becomes more serious. The novel small molecular anti-MRSA drugs play an important role in the treatment of MRSA infection in clinic. Several immunotherapy drugs in clinical trial stage showed unique results to MRSA infected disease. This review briefly summarizes the latest development of active and passive immunotherapy for the treatment of MRSA infection

关 键 词：耐甲氧西林金葡菌 主动免疫 被动免疫 疫苗 单克隆抗体 

分 类 号：R378.11[医药卫生—病原生物学] R457.2[医药卫生—基础医学]